ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2572

Protective and Therapeutic Effects of Growth Hormone on Collagen-Induced Arthritis

Ricardo J. Villares1, Gabriel Criado2, Rosa P Gomariz3, Yasmina Juarranz3, Javier Leceta3, Graciela Cascio4, Jose L. Pablos5 and Mario Mellado6, 1Immunology & Oncology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain, 2Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, 3Cellular Biology, School of Biology. Universidad Complutense de Madrid, Madrid, Spain, 4Immunoloy & Oncology, Centro Nacional de Biotecnología-CSIC, Madrid, Spain, 5Instituto de Investigacion Hospital, Madrid, Spain, 6Immunology and Oncology, Centro Nacional de Biotecnología. CNIC, Madrid, Spain

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Animal models, arthritis management, growth factors, prevention and treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Inflammatory (M1) macrophages and T helper 17 (TH17) cells are central to rheumatoid arthritis (RA) pathogenesis.  Although the growth hormone [GH]/insulin-like growth factor 1 axis is involved in joint repair, little is known of the GH function in control of innate and adaptive immunity.  To analyze the potential clinical and immunological effects of GH treatment in RA, we use a murine collagen-induced arthritis (CIA) model, compile data on disease development, and study the molecular and cellular mechanisms involved.

Methods:

We tested the in vivoinhibitory effect of GH in a murine CIA model.  Disease was induced in 8- to 10-week-old transgenic C57BL/6J mice expressing bovine GH (Tg-bGH), Wild type (WT) littermates, and DBA1 mice, by intradermal immunization with 200 mg chicken type II collagen (CII) in complete Freund’s adjuvant.

To assess clinical effectiveness in DBA1 mice, we administered recombinant human (rh)GH subcutaneously for 20 days as a therapeutic regime.  At disease onset, DBA1 mice with a clinical arthritis score >1 (scale: 0-12) were randomized to receive rhGH treatment (100 mg/kg/day; n = 10) or vehicle (n= 10).  Statistical differences were analyzed by ANOVA and Mann-Whitney U-test.  P values <0.05 were considered significant.

GH effect was analyzed by flow cytometry (FC) to detect Treg (FoxP3+), Th1 (IFNg+) and Th17 (IL17+) CD4 T cells in secondary lymphoid tissues.  T cell responses were evaluated in vitroby CII-induced proliferation as measured by incorporation of the colorimetric reagent WST-1.  Serum levels of anti-CII antibodies were determined by ELISA.  T cell differentiation was determined in various tissues by quantitative PCR using probes for the specific transcription factors t-bet, RORgT and FoxP3, and for Th1/Th17/Treg-specific cytokines.  To test the ability of dendritic cells (DC) from WT and Tg-bGH mice to present antigen to T cells from OT-II mice, we loaded DC with the ovoalbumin peptide 329-337 and assessed T cell activation and proliferation by FC and CellTrace Violet dilution.

Results:

We found significant reduction in GH transgenic compared to control mice in disease incidence (25% vs. 70%) and onset time (34.5±1.7 vs. 23.2±3.5; p<0.001), and a tendency to lower clinical scores (1.5±0.7 vs. 3.8±1.8 at day 37 post-immunization, p=0.13).  GH treatment of arthritic DBA1 mice ameliorated disease, with a reduced cumulative arthritis score (2.5±0.8) compared to the vehicle group (4.0±0.6)(p=0.06).

 The molecular mechanism involves an increased Treg/Th17 ratio and a shift to a non-pathogenic phenotype in Th17 cells and in joint-infiltrated macrophages in Tg-bGH mice; these mice had a M2 (non-inflammatory) macrophage profile compared to M1 in WT counterparts.  Although serum anti-CII antibodies and in vitrocollagen-induced T cell proliferation were low in Tg-bGH mice, DC showed no differences in phenotype or in antigen-presenting activity; anti-CD3+IL2-induced T cell activation was similar in both mouse groups.

Conclusion: GH prevents and has therapeutic effects in  CIA by modulating macrophage and Th17 cell differentiation. Targeting the GH signaling pathway could thus be a therapeutic approach to RA treatment.


Disclosure: R. J. Villares, None; G. Criado, None; R. P. Gomariz, None; Y. Juarranz, None; J. Leceta, None; G. Cascio, None; J. L. Pablos, None; M. Mellado, None.

To cite this abstract in AMA style:

Villares RJ, Criado G, Gomariz RP, Juarranz Y, Leceta J, Cascio G, Pablos JL, Mellado M. Protective and Therapeutic Effects of Growth Hormone on Collagen-Induced Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/protective-and-therapeutic-effects-of-growth-hormone-on-collagen-induced-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/protective-and-therapeutic-effects-of-growth-hormone-on-collagen-induced-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology